ArticleBlood cancer journal2025
Value of serum-free light chain measurements in response and progression assessment in multiple myeloma with monoclonal protein measurable by electrophoresis.
Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Hematologic response assessment in monoclonal gammopathy of renal significance: critical appraisal of current criteria.Frontiers in medicine · 2026Article
- Recent Updates and Advancements in the Diagnosis and Management of Plasma Cell Dyscrasias.Cureus · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uniform assessment of response to treatment is crucial to managing multiple myeloma (MM) and developing new therapies. Measurement of monoclonal protein forms the cornerstone of disease assessment in MM. According to International Myeloma Working Group (IMWG) guidelines, serum-free light chain (sFLC) is included in MM response assessment in patients with no measurable disease by electrophoresis and to define stringent complete response. We retrospectively analyzed the independent value of serial FLC on response and progression assessments in 839 patients with measurable disease by sFLC as well as serum/urine electrophoresis. A significant association was observed between sFLC and electrophoretic responses during initial therapy and at best response (p < 0.001). This study revealed comparable percentage changes in serial dFLC and urine M-protein, with parallel trends (p < 0.001) and strong correlations (r 0.55-0.79, p < 0.001). The response was detected earlier by sFLC (1.1 months, 95% CI 1.06-1.17), and sFLC ≥ PR after two cycles of induction demonstrated a strong predictive value for subsequent electrophoresis responses (OR 9.33, p < 0.001). Following induction, no difference in PFS was observed between very good partial response (VGPR) as determined by sFLC, sPEP, and uPEP (p = 0.538). The median second-PFS for patients with only sFLC-progression disease (PD) was similar to those with urine M-protein PD with or without sFLC-PD (HR 1.28, 95% CI 0.77-2.13, p 0.334). However, the median overall survival from the first relapse was significantly better for patients with only sFLC-PD (HR 1.87, 95% CI 1.07-3.27, p 0.03). Among patients with PD, 12% had sFLC as the only detectable tumor marker at the time of second-line therapy. This study supports the incorporation of serial sFLC measurements for monitoring response and progression in MM, even in patients with electrophoretic measurable disease, and further advocates replacing 24-h urine with serial sFLC in response assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.